Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
Zacks Investment Research on MSN
Moderna (MRNA) may report negative earnings: Know the trend ahead of next week's release
The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...
April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...
A new effort to prepare for future avian influenza outbreaks is moving forward, despite a major funding setback.
April 21 (Reuters) - Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the ...
A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results